Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma

Cancer Letters

Volumn 257, Issue 1, 2007, Pages 136-144

  Pasquali, Lorenzo ^a,c   Bedeir, Ahmed ^b   Ringquist, Steven ^a   Styche, Alexis ^a   Bhargava, Rohit ^b   Trucco, Giuliana ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; CpG islands; GSTP1; Methylation; Pyrosequencing; RASSFA1

Indexed keywords

GLUTATHIONE TRANSFERASE P1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UVOMORULIN;

ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; BREAST LESION; CANCER GROWTH; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 34648846673     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.010     Document Type: Article

References (29)

1. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., and Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1 (1995) 686-692
2. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
3. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv. Exp. Med. Biol. 532 (2003) 39-49
4. Bird A. The essentials of DNA methylation. Cell 70 (1992) 5-8
5. Holliday R., and Grigg G.W. DNA methylation and mutation. Mutat. Res. 285 (1993) 61-67
6. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999) 103-107
7. Rountree M.R., Bachman K.E., Herman J.G., and Baylin S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 20 (2001) 3156-3165
8. Jones P.A. DNA methylation and cancer. Oncogene 21 (2002) 5358-5360
9. Agathanggelou A., Honorio S., Macartney D.P., Martinez A., Dallol A., Rader J., Fullwood P., Chauhan A., Walker R., Shaw J.A., Hosoe S., Lerman M.I., Minna J.D., Maher E.R., and Latif F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20 (2001) 1509-1518
10. Nass S.J., Herman J.G., Gabrielson E., Iversen P.W., Parl F.F., Davidson N.E., and Graff J.R. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 60 (2000) 4346-4348
11. Sirchia S.M., Ferguson A.T., Sironi E., Subramanyan S., Orlandi R., Sukumar S., and Sacchi N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene 19 (2000) 1556-1563
12. Esteller M., Corn P.G., Urena J.M., Gabrielson E., Baylin S.B., and Herman J.G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58 (1998) 4515-4518
13. Bae Y.K., Brown A., Garrett E., Bornman D., Fackler M.J., Sukumar S., Herman J.G., and Gabrielson E. Hypermethylation in histologically distinct classes of breast cancer. Clin. Cancer Res. 10 (2004) 5998-6005
14. Karpf A.R., and Jones D.A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21 (2002) 5496-5503
15. Herranz M., and Esteller M. DNA methylation and histone modifications in patients with cancer: Potential prognostic and therapeutic targets. Methods Mol. Biol. 361 (2007) 25-62
16. Shames D.S., Minna J.D., and Gazdar A.F. Methods for detecting DNA methylation in tumors: From bench to bedside. Cancer Lett. (2006) 187-198
17. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93 (1996) 9821-9826
18. Shaw R.J., Akufo-Tetteh E.K., Risk J.M., Field J.K., and Liloglou T. Methylation enrichment pyrosequencing: Combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res. 34 (2006) e78
19. Tost J., Dunker J., and Gut I.G. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 35 (2003) 152-156
20. Colella S., Shen L., Baggerly K.A., Issa J.P., and Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35 (2003) 146-150
21. Tost J., El Abdalaoui H., and Gut I.G. Serial pyrosequencing for quantitative DNA methylation analysis. Biotechniques 40 (2006) 721-726
22. Shaw R.J., Liloglou T., Rogers S.N., Brown J.S., Vaughan E.D., Lowe D., Field J.K., and Risk J.M. Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: Quantitative evaluation using pyrosequencing. Br. J. Cancer 94 (2006) 561-568
23. Marsh S. Pyrosequencing(R) applications. Methods Mol. Biol. 373 (2006) 15-24
24. Honorio S., Agathanggelou A., Schuermann M., Pankow W., Viacava P., Maher E.R., and Latif F. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 22 (2003) 147-150
25. Ringquist S., Styche A., Rudert W.A., and Trucco M. Pyrosequencing(R)-based strategies for improved allele typing of human leukocyte antigen loci. Methods Mol. Biol. 373 (2006) 115-134
26. R.J. Shaw, G.L. Hall, D. Lowe, N.L. Bowers, T. Liloglou, J.K. Field, J.A. Woolgar, J.M. Risk, CpG island methylation phenotype (CIMP) in oral cancer: Associated with a marked inflammatory response and less aggressive tumour biology, Oral. Oncol., in press, doi:10.1016/j.oraloncology.2006.10.006.
27. Widschwendter M., Siegmund K.D., Muller H.M., Fiegl H., Marth C., Muller-Holzner E., Jones P.A., and Laird P.W. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64 (2004) 3807-3813
28. Shinozaki M., Hoon D.S., Giuliano A.E., Hansen N.M., Wang H.J., Turner R., and Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res. 11 (2005) 2156-2162
29. Fackler M.J., McVeigh M., Evron E., Garrett E., Mehrotra J., Polyak K., Sukumar S., and Argani P. DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int. J. Cancer 107 (2003) 970-975